Charcot–Marie–Tooth Disease With Episodic Rhabdomyolysis Due to Two Novel Mutations in the β Subunit of Mitochondrial Trifunctional Protein and Effective Response to Modified Diet Therapy

Yuqing Guan 1*, Yanxia Zhang 2, Xin-Ming Shen 3, Liang Zhou 1, Xuan Shang 2, Yu Peng 1, Yafang Hu 1 and Wei Li 1

1 Department of Neurology, Nanfang Hospital, Southern Medical University, Guangzhou, China, 2 Department of Medical Genetics, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China, 3 Department of Neurology, Mayo Clinic, Rochester, MN, United States

A 29-year-old female experienced chronic progressive peripheral neuropathy since childhood and was diagnosed with Charcot–Marie–Tooth disease (CMT) at age 15. She developed recurrent, fever-induced rhabdomyolysis (RM) at age 24. EMG studies showed decreased amplitude of compound muscle action potential, declined motor conductive velocity, and absence of sensor nerve action potential. Acylcarnitine analysis revealed elevated C16-OH, C18-OH, and C18:1-OH. Muscle biopsy showed scattered foci of necrotic myofibers invaded by macrophages, occasional regenerating fibers, and remarkable muscle fiber type grouping. Whole-exome sequencing identified two novel heterozygous mutations: c.490G>A (p.G164S) and c.686G>A (p.R229Q) in HADHB gene encoding the β-subunit of mitochondrial trifunctional protein (MTP). Reduction of long-chain fatty acid via dietary restrictions alleviated symptoms effectively. Our study indicates that the defect of the MTP β-subunit accounts for both CMT and RM in the same patient and expands the clinical spectrum of disorders caused by the HADHB mutations. Our systematic review of all MTPD patients with dietary treatment indicates that the effect of dietary treatment is related to the age of onset and the severity of symptoms.

Keywords: mitochondrial trifunctional protein deficiency, HADHB, peripheral neuropathy, Charcot-Marie-Tooth disease, rhabdomyolysis

INTRODUCTION

Mitochondrial trifunctional protein (MTP) is a hetero-octamer complex consisting of four α subunits encoded by HADHA gene and four β subunits encoded by HADHB gene. It catalyzes three reactions in the fatty acid β-oxidation process by three enzymes located in the inner membrane of the mitochondria: long-chain enoyl-CoA hydrolase (LCEH) and long-chain 3-hydroxy-acyl-CoA dehydrogenase (LCHAD) contained in α subunits, and long-chain 3-ketoacyl-CoA thiolase (LCKT)
Mitochondrial trifunctional protein deficiency (MTPD) is a rare autosomal recessive disorder caused by pathogenic variants of HADHA or HADHB. These variants disrupt MTP function with different severities resulting in complete MTP deficiency, isolated LCHAD or isolated LCKT deficiency (5). MTPD is clinically classified into three subtypes: (1) neonatal-onset type with cardiomyopathy and high mortality, (2) infant-onset type showing episodic hypoketotic hypoglycemia and hepatic dysfunction, and (3) later-onset neuromyopathic type with a wider spectrum of peripheral neuropathy, myopathy symptoms, or both (6). However, neither genotype–phenotype relation nor biochemistry–clinic correlation has been established due to its heterogeneities.

Charcot–Marie–Tooth (CMT) disease is an inherited peripheral motor and sensory neuropathy. It was traditionally classified into demyelinating, axonal, and intermediate subtypes based on nerve conduction velocity. A gene-based classification with mode of inheritance and neuropathy type was proposed based on nerve conduction velocity. A gene-based classification classified into demyelinating, axonal, and intermediate subtypes peripheral motor and sensory neuropathy. It was traditionally due to its heterogeneities.

Rhabdomyolysis (RM) is characterized by skeletal muscle damage resulting in the release of intracellular muscle components such as myoglobin, creatine kinase (CK), aldolase, lactate dehydrogenase, and electrolytes into the bloodstream and extracellular space. RM symptoms can present from asymptomatic to renal failure depending on diverse environmental and genetic factors. Genetic defects associated with RM often account for various inherited neuromuscular and metabolic disorders including glycogen and fatty acid metabolism disorders, muscular dystrophies, and mitochondrial diseases (14). Although mitochondrial diseases usually prefer reduced ATP production due to primary downstream impairment of oxidative phosphorylation, additional essential metabolic processes such as beta-oxidation of long-chain fatty acids also occur within mitochondria. A total of 18 patients with RM caused by mutations in the HADHB gene were reported to date (patient 5–16, 24, 26, 29–32 in Table 1).

To date, seven patients with RM episodes and chronic peripheral neuropathy were characterized based on clinical manifestations and electrophysiological properties (patients 3, 6–8, 14–16 in Table 1). However, none were considered as CMT. Patients with various clinical manifestations including CMT or RM caused by HADHB mutations have been reported (22), but whether the HADHB mutation causes both CMT and RM in the same patient has not yet been determined. Moreover, early diagnosis of MTPD is now more easily achievable with newborn screening and next-generation sequencing (NGS), but studies on the treatment of MTPD have not increased proportionally. Here, we report a Chinese patient diagnosed with both CMT and RM caused by novel HADHB mutations with good response to dietary treatment.

## METHODS

### Research Protocol and Consent Form

The study was approved by the Ethics Committee of Nanfang Hospital, Southern Medical University. The patient and the parents provided written informed consent for participation and publication of this study.

### Routine Examinations, Blood Acylcarnitine Analysis, and Urine Organic Acid Test

Routine blood examinations were implemented to evaluate levels of glucose, lipid, electrolytes, plasma lactic acid, hepatic and retinal function, serum creatine kinase (CK), myoglobin concentration, and parathyroid hormone. Chest X-ray, electrocardiogram, abdominal ultrasonography, and pulmonary ventilation test were also performed. We used gas chromatography-tandem mass spectrometry to assess blood acylcarnitine and urine organic acid levels.

### Nerve Conduction Study and Electromyography

Nerve conduction study and concentric needle electromyography (EMG) were performed with a Keypoint 9033A07 EMG machine (Dantec Corporation, Denmark). We also performed sympathetic skin response (SSR) and Ewing’s test to assess the autonomic nervous system function.

### Skeletal Muscle Biopsy and Histochemical Staining

Biopsy of the left biceps, freeze fixation, frozen section, and staining of muscle specimen were performed according to the standard procedure in our laboratory (27).

### Genomic DNA Extraction and Whole-Exome Sequencing

EDTA-anticoagulated peripheral blood was collected, and genomic DNA was extracted. Whole-exome sequencing (WES) was performed using a standard PCR-based next-generation sequencing procedure on Illumina high throughput sequencer. The detected mutations were verified by Sanger sequencing. The pathogenicity of detected variations was predicted by SIFT, Polyphen-2, Mutation taster, PANTHER, and PROVEAN. I-Mutant 2.0 was used to assess the variant protein stability. The tertiary structure of the mutant protein was modeled by Swiss model software. Spatial structures of wild-type and mutant HADHB proteins were compared with PyMol.

## RESULTS

### Clinical Information

A 29-year-old female patient was admitted due to childhood-onset progressive weakness and atrophy of distal limbs and intermittent fever-induced exacerbation of weakness for the past 5 years. She was born normally with normal movement...
| Case No/Gender | Age at diagnosis | Evidence of myopathy/onset age | Evidence of PN/onset age | NCS/EMG | Gene | Mutation classification | cDNA | AA | Reference |
|---------------|-----------------|-------------------------------|-------------------------|---------|------|------------------------|------|-----|-----------|
| 1/F 18 years 9 years ND | 9 years | 9 years | Y | Y | PN | HADHA com het | 453 + 1G > T/955G > A | splicing defect/ Gly319Ser | (15) |
| 2/M 13 years ND | ND 55 years | Childhood | 5 years | 9 years | Y | Y | ND | ND | HADHB homo | 712C > T | Arg236Thr | (15) |
| 3/F 12 years ND | 10 years | Childhood | 5 years | 10 years | Y | Y | ND | ND | HADHB homo | 407T > C | Gly26Asp | (16) |
| 4/F 14 years ND | ND 2 years | Childhood | 5 years | 4 years | Y | Y | ND | ND | HADHB homo | 176G > A/740G > A | Gly26Asp | (16) |
| 5/F 18 years ND | ND 5 years | Childhood | 5 years | 5 years | Y | Y | ND | ND | HADHB homo | 1175C > T | Ala392Val | (16) |
| 6/F 6 years ND | ND 3 years | Childhood | 5 years | 3 years | Y | Y | ND | ND | HADHB homo | 1175C > T | Ala392Val | (16) |
| 7/F 17 years ND | ND 6 years | Childhood | 5 years | 6 years | Y | Y | ND | ND | HADHB homo | 490G > A/686G > A | Gly164Ser | (16) |

Patients with both myopathy and neuropathy

| Case No/Gender | Age at diagnosis | Evidence of myopathy/onset age | Evidence of PN/onset age | NCS/EMG | Gene | Mutation classification | cDNA | AA | Reference |
|---------------|-----------------|-------------------------------|-------------------------|---------|------|------------------------|------|-----|-----------|
| 1/F 9 years | 9 years | ND | >2xULN | 9 years | 9 years | Y | Y | PN | HADHA com het | 453 + 1G > T/955G > A | splicing defect/ Gly319Ser | (15) |
| 2/M ? | ? | ? | Elevated | ? | ? | ND | ND | ND | HADHB homo | 845T > A | Val246Asp | (16) |
| 3/M 7 years | Y | Y | 50,000 | Y | Y | ND | ND | ND | HADHB homo | 1528G > C/ 180 + 3A > G | Glu510Gln/Thr37SerfsX6 | (17) |
| 4/M 53 years N | ND | 48y | 190,864 | N | N | ND | Y | PN | HADHB com het | 1528G > C/ 180 + 3A > G | Glu510Gln/Thr37SerfsX6 | (17) |

Patients with neuropathy only

| Case No/Gender | Age at diagnosis | Evidence of myopathy/onset age | Evidence of PN/onset age | NCS/EMG | Gene | Mutation classification | cDNA | AA | Reference |
|---------------|-----------------|-------------------------------|-------------------------|---------|------|------------------------|------|-----|-----------|
| 18/M 19 years | N | ND N | Normal | Y | Y | N | Y | PN | HADHB homo | 184A > G/340A > G | Thr62Ala/Asn114Ser | (12) |
| 19/M 5 years | N | ND N | 400 | Y | Y | N | Y | PN | HADHB homo | 489G > A/1175C > T | Gly163Asp/Ala392Val | (12) |
| 20/M 34 years | N | N N | ND | 5 years | 5 years | Y | 5 | PN | HADHB homo | 210-1G > C/686G > A | 15aa deletion/ Arg229Leu | (12) |
| 21/F 37 years | N | N N | ND | 6 years | ND | Y | Y | PN | HADHB homo | 210-1G > C/686G > A | 15aa deletion/ Arg229Leu | (12) |
| 22/F 29 years | N | ND N | Childhood | Y | Y | PN | HADHB homo | 955G > A | Gly319Ser | (13) |
| 23/M 24 years | N | ND N | Childhood | Y | Y | PN | HADHB homo | 955G > A | Gly319Ser | (13) |
**TABLE 1 | Continued**

| Case No /Gender | Age at diagnosis | Evidence of myopathy/onset age | Evidence of PN/onset age | NCS/EMG | Gene | Mutation classification | cDNA | AA | Reference |
|-----------------|-----------------|--------------------------------|--------------------------|---------|------|------------------------|------|-----|-----------|
|                 | Prox W/MP | Exe Intol | RM | CK/max | Dist W/A | H/F deform | S abnorm | Refl- |
| 24/M 7 months | ND | Y | Y | 165,000 | ND | N | ND | ND | ND | HADHA | com het | 1528G>C/1678C>T Glu474Gln/Arg524ter (16) |
| 25/M 4-5 years | ND | 1.5xULN | ND | ND | ND | ND | ND | ND | HADHA | com het # | 180 + 3A > G/1528G>C Glu510Gln/Arg524ter (15) |
| 26/F 12 years | ND | 4 years | 37,935 | ND | ND | ND | ND | ND | HADHB | com het | 919A>G/1165A>G Asn307Asp/Asn389Asp (24) |
| 27/F 12 years | Y? | ND | ND | 1,000 | Y? | ND | ND | ND | ND | HADHB | com het | 182G>A/740G>A Arg28His/Arg214His (16) |
| 28/M 10 months | Y? | N | elevated | Y? | N | ND | ND | ND | ND | HADHB | com het | 181C>T/314A>G Arg28His/Arg94Gly (16) |
| 29/F 8 years | Y | Y | Y | 29,960 | Y? | N | ND | ND | ND | HADHB | homo | 901G>A Gly268Ser (16) |
| 30/M 3 years | Y | Y | elevated | Y? | N | ND | ND | ND | ND | HADHB | com het | 397A>C/881C>G Thr133Pro/Pro261Arg (16) |
| 31/F 13 years | childhood | 9 years | 22,885 | ND | ND | ND | ND | ND | ND | HADHB | com het | 520 C>T/1331 G>A Arg174Pro/Arg441Lys (23) |
| 32/M 15 years | 15 years | 15 years | 121,800 | N | N | ND | ND | ND | ND | HADHB | homo | 1331G>A Arg441Lys (26) |

Patients with myopathy only

Case number 1 to 17: patients with both myopathy and peripheral neuropathy; Case number 18 to 23: patients with pure peripheral neuropathy; Case number 24 to 32: patients with pure myopathy.

AA, Amino acid changes; CK/max, CK elevation/maximal CK; com het, compound heterozygous; Dist W/A, distal weakness/atrophy; Elevated, elevated, but the precise number was not available; ESW, episodic severe weakness; Exe Intol, exercise intolerance; H/F deform, hand/feet deformity; homo, homozygous missense; MP, muscle pain; ND, not described; PN, peripheral neuropathy; Prox W, proximal weakness; Refl-, absent tendon reflexes; RM, rhabdomyolysis; S abnorm, sensory abnormality; ULN, upper limit of normal.

# Compound heterozygosity was not confirmed by analysis of parents.
development milestones in her early childhood. At the age of six, she started to feel tired after exercise and took frequent rest breaks during long walks. She was obviously inferior to her peers in sports performances. She gradually developed muscle atrophy in her hands and feet, weakness in legs, and abnormal gait. When she was 13 years old, she received heel tendon surgery, which temporarily improved her gait. At age 15, she was diagnosed with Charcot–Marie–Tooth disease in another neuromuscular disease clinic. She received physical therapy over the following years with little improvement. When she was 24 years old, she experienced marked exacerbation of weakness with severe general muscle pain after a fever induced by infection of upper respiratory tract. Thereafter, her strength deteriorated during each fever occurrence, causing her to remain bedbound for several days. Five months before her admission, she experienced her worst general weakness after developing a fever due to influenza. The patient had difficulty chewing and extending her neck, complained of severe pain in all extremities and trunk muscles, and noticed dark-colored urine. She was admitted to a local hospital and diagnosed with rhabdomyolysis with creatine kinase level >10,000 U/L. After hydration and nutritional support treatment for several days, she recovered to a pre-infection level. One month before her admission to our hospital, she underwent another infection-induced episode of exacerbation with similar symptoms and CK changes.

Physical examination showed normal cranial nerve signs. The muscular volumes in her upper arms, forearms, and proximal thighs were normal. Mild muscle atrophy was found in both hands with grip strength of 4/5 (Medical Research Council grade scale). She had muscle atrophy in bilateral distal thighs and legs with high-arched feet. Muscle strength was 2/5 in foot dorsal extension and 4/5 in hip flexion, knee extension, knee flexion, and foot plantar flexion. Pain sensation of upper limbs was normal, whereas vibration sensation below the elbow was decreased, and pain and vibration sensation below both knees were diminished. Tendon reflexes in all extremities were absent. She had been wheelchair bound for the last 2 years and needed assistance to rise from the wheelchair. She could stand on her own but had difficulty walking, with a mixture of stoppage and waddling gait. Ophthalmic examination showed normal findings. Her parents were asymptomatic with normal muscle strength, tendon reflex, and sensation.

Routine Blood Test and Other Examinations
Both serum CK and myoglobin levels were elevated to 450 and 336 IU/L from normal ranges of 2–178 and 0–110 IU/L, respectively. The plasma lactic acid was mildly increased to 2.9 mmol/L from a normal range of 0–2.2 mmol/L. Abdominal ultrasound showed fatty liver. Serum calcium, phosphate, parathyroid hormone, and other routine tests were normal. Head CT scan showed no abnormality.

Electromyography Studies
Motor nerve conductions were measured in bilateral median, ulnar, tibial, and peroneus communis nerves. Compound muscle action potential (CMAP) and motor conductive velocity (MCV) were both reduced in all tested nerves. The CMAP of upper extremities ranged from 4.0 to 5.3 mV, whereas the CMAP of lower extremities ranged from 0.47 to 2.3 mV. The MCV of upper extremities ranged from 26.5 to 46.0 m/s, whereas the MCV of lower extremities ranged from 29.2 to 38.5 m/s. The F-wave rate of the right tibial nerve decreased to 20% of control with normal latency. Sensor nerve conductance was measured in bilateral median, ulnar, peroneus communis, and sural nerves. No sensory nerve action potential (SNAP) was recorded in any of the tested nerves. Electromyography studies were performed in the right deltoid, extensor digitorum communis, vastus medialis, and tibial anterior muscles. All showed moderate fibrillation and positive sharp waves with reduced interference pattern. Compared with control with the same age group, the duration of motor unit potential (MUP) was prolonged from 18% to 67%. Sympathetic skin response and Ewing's test showed normal function of unmyelinated nerve fibers.

Metabolic Tests
Acylcarnitine analysis of blood spot obtained during the interval of rhabdomyolysis attacks revealed mild elevation of C16-OH (0.18 µmol/L vs. normal range 0.01–0.10 µmol/L), C18-OH (0.07 µmol/L vs. normal range 0.00–0.05 µmol/L), and C18:1-OH (0.15 µmol/L vs. normal range 0.01–0.10 µmol/L). Urine organic acid level was normal. The results indicate a biochemical phenotype of an MTP multienzyme complex deficiency.

Muscle Biopsy
Biopsy of the left biceps revealed scattered foci of necrotic myofibers invaded by macrophages and occasional regenerating fibers, which were consistent with the episode of rhabdomyolysis (Figures 1A,B,D). No pathological changes suggested abnormal lipid metabolism, abnormal glucose metabolism, or abnormal mitochondria. A small cluster of atrophic myofibers was found (Figure 1C). No target fiber was investigated. Remarkable muscle fiber type grouping appeared on NADH-TR stain and on fast-myosin and slow-myosin immunohistochemistry (IHC) stain, indicating a long-standing process of reinnervation, which was consistent with the clinical procedure of CMT (Figures 1C,E,F).

Genetic Analysis
Whole-exome and Sanger sequencing identified two heterozygous variants in HADHB gene (NM_000183.2) encoding MTP β subunit: c.490G>A (p.G164S) in the paternal allele and c.686G>A (p.R229Q) in the maternal allele (Figure 2A). The c.490G>A was not found in variance database or literature, whereas c.686G>A variant has been listed in the ClinVar database (variation ID: 253051) with uncertain clinical significance. Both variants were predicted to be damaged mutation by Mutation Taster, PROVEAN, Polyphen-2, and PANTHER analysis, and to decrease the stability of the protein structure by I-Mutant analysis. Both mutations are located in the N-terminal domain of HADHB protein, and mutant residues are conserved in all species (Figure 2B). Structure modeling showed that compared with wild-type protein, a part of the α-helix in N-terminal domain of G164S protein changes into a strand, and a part of strand in N-terminal domain of R229Q protein turns...
into a helix (Figure 2C). The tail structure in G164S protein was also altered.

**Treatment**
The patient was given a low-fat, high-carbohydrate diet. She ate cereals (including rice, corn, brown rice, flour, and sorghum), bean products (other than soybeans), pig blood, chicken blood, vegetables, and fruits without controlling the total amount. She also consumed a total of 50 g of steamed sea fish, shrimp, and peeled poultry meat daily. She drank 500 ml of skimmed milk every day and consumed one egg white and 10 g of nuts as well. She supplemented with 35 g of medium-chain triglyceride and 30 g of whey protein powder, which were divided into three doses daily. The daily fat intake was limited to 43 g, including 36 g of medium-chain fat and 7 g of long-chain essential fat. She also had 100 mg of L-carnitine with multivitamin tablet daily to prevent deficiency of lipid soluble vitamins. She avoided cooking oil and prolonged fasting and exercise. The motor function of the patient gradually improved and reached a plateau after 1 year of the diet treatment. After that, she stopped taking medium-chain triglyceride powder because of its poor taste. She still follows the low-fat, high-carbohydrate diet principle. In a recent follow-up, ~2.5 years after the diet treatment, neurological examination showed that muscle strength was 4/5 in grip, 2/5 in foot dorsal extension, and 4/5 in hip flexion, which were comparable with initial measurement. However, the power of knee extension, knee flexion, and foot plantar flexion improved to 5/5. Examination of muscle volume, sensation, and tendon reflexes showed results similar to the start of the study. The result of a 6-min walking test was 225 m. The motor function of the patient improved
Identification of disease-associated HADHB mutations. (A) Sanger sequencing showing the compound heterozygous mutations, c.490G>A and c.686G>A, in the HADHB gene of the patient and heterozygous mutation in her parents. (B) The glycine residue at codon 164 and arginine residue at codon 229 of HADHB protein are highly conserved among different species (shown in red boxes). (C) Comparison of spatial structure of the wild and mutant HADHB proteins as indicated. The HADHB protein has two domains where the gene encodes thiolase enzyme, N-terminal domain (yellow chain), and C-terminal domain (blue chain). Modified points are marked with a red rectangle.
greatly compared with pretreatment levels, when she could barely walk and required another person to carry her up and down the stairs. Now, she can walk up to the third floor without taking a break. She did not experience RM again, even during the process of respiratory tract infection and fever, which happened 6 months after the start of dietary treatment. The patient works as a volunteer in a nursing home, helping elderly individuals with documents and computer-related matters.

**DISCUSSION**

Based on the clinical symptoms, electrophysiological findings, acylcarnitine analysis results, and pathologic changes, and episodic fever-triggered RM at a later age, our patient was diagnosed with MTPD with manifestation of childhood-onset CMT and paroxysmal RM after adulthood and showed good response to dietary therapy. We traced the CMT and RM of this patient into two novel mutations G164S and R229Q in HADHB with each likely altering the structure of the protein. To our knowledge, this is the first report of CMT and RM caused by HADHB mutations in the Chinese population.

To date, 32 total patients with neuromyopathic MTPD were reported with 8 harboring HADHA mutations and 24 carrying HADHB mutations (Table 1). Of 32 patients, six displayed peripheral neuropathy, nine with myopathy, and 17 with both peripheral neuropathy and myopathy (Table 1). We classify the clinical manifestations of neuromuscular MTPD into three categories: (1) peripheral neuropathy with symptoms and electrophysiological changes of CMT—usually more severe in lower limbs, (2) myopathy presented as episodic rhabdomyolysis triggered by stressful situations and with milder myopathic symptoms such as exercise intolerance, proximal weakness, and muscle pain, and (3) other complications, such as pigmentary retinopathy and hypoparathyroidism. The neuromuscular (NM) subtype of MTPD was previously defined as mild or adult-onset (22, 28), but that is not always the case. Although the age of onset in some MTPD patients is as late as 48 years of age (17), the first episode of rhabdomyolysis may occur within the first year of life with life-threatening symptoms (16). Some patients survived from infant hepatopathy but developed PN in later life (20). MTPD patients with NM defects demonstrated a very wide spectrum of clinical manifestations. The features of PN can be subtle or even subclinical in some patients (17). On the other hand, in patients with obvious peripheral neuropathy symptoms, myopathic features such as mild proximal weakness and exercise intolerance might be overlooked. That was the case with our patient. With detailed inquiry, she recalled fatigue after exercise since childhood and general fatigue during her menstrual period. Our systematic review on all reported patients with mutations in HADHA and HADHB suggests there is no correlation between genotype and phenotype.

Early-onset axonal CMT caused by heterozygous mutations in HADHB was first described in two Korean siblings in 2013 (11). Infant- and childhood-onset CMT caused by HADHB mutations were characterized in two unrelated Chinese patients. Recently, a homozygous missense HADHA mutation was reported in two Iranian siblings with clinical manifestation of axonal form of CMT (CMT2) (12, 13). Recently, it was suggested that peripheral neuropathy related to HADHB mutations may be manifested as axonal CMT without other MTP deficiency symptoms (29). However, the diagnosis of CMT in patients with MTPD was considered “misdiagnosed” in another report (6). The present study supports the notion that HADHA- or HADHB-related motor and sensory neuropathy should be considered as a CMT subtype. Our patient was diagnosed with axonal CMT at the age of 15 based on her clinical course and electrophysiological changes without identification of pathogenic mutation. If the HADHB gene had been included in the screening panel for hereditary peripheral neuropathy, our patient would have received the correct genetic diagnosis 14 years earlier, resulting in proper treatment with better outcomes and improved quality of life. Her rhabdomyolysis episodes could have been avoided. Thus, we report a new subtype of CMT with metabolic myopathy due to MTPD deficiency caused by mutations of HADHB gene, suggesting that all CMT patients without definite pathogenic mutations should be screened for mutation in HADHA and HADHB genes.

Prognosis of MTPD may be significantly improved by diet-modulating therapy with appropriate prevention of energy decompensation (20). Dietary modification and avoidance of stressful triggers are particularly effective in preventing attacks of rhabdomyolysis (31). Guidelines on treatment of MTPD are not yet agreed upon and established to date. The current recommendation on dietary modification includes carbohydrate-based diet with supplementation of medium-chain triglycerides and restriction of long-chain fatty acid (5, 32). We reviewed literatures on dietary treatment of all MTPD patients. Eighteen patients with detailed descriptions of therapeutic strategies and clinical outcomes are summarized in Table 2. We found that the effect of dietary treatment was related to the age of onset and the severity of symptoms. All four MTPD patients of neonatal-onset subtype died, even after timely treatment, with a maximum life span of only 9 months. In six patients with infant-onset hypoglycemia and/or hepatopathy, two died at nine and 10 months, respectively, and four had favorable outcomes. Five patients with NM subtype had positive reactions to dietary treatment. It is noteworthy that three patients (patients 11, 13, and 17 in Table 2) with early onset and severe symptoms improved explicitly after treatment. These patients were diagnosed and treated at age 14 years (patient 11), 7 years (patient 13), and 10 years (patient 17), respectively. The mutations were in HADHA for patient 11 and HADHB for patients 13 and 17. In these patients, more treatment points (at least five out of 10) were implemented. The dietary treatment of our case, which started at the age of 29 years, also achieved satisfactory results, suggesting that MTPD is more treatable than expected. However, in the literature, late-onset neuromuscular MTPD with outcome of dietary treatment only accounted for a small portion of this subtype. A possible reason is that adult patients showed poor compliance to the recommended dietary plan (5, 19). Our patient reacted well because we tailored a diet regimen in accordance with the above principles by combining formula nutrients with selected foods, which was
| No | Age       | Gender | Onset age | Symptom summary                                                                 | Subtype   | Gene       | Mutation       | Treatment | Outcome                                  | Reference |
|----|-----------|--------|-----------|--------------------------------------------------------------------------------|-----------|------------|----------------|-----------|------------------------------------------|-----------|
| 1  | 48 days   | F      | newborn   | Hyperammonemia; hyperlactatemia                                               | Neonatal  | HADHA      | homo c.1689+2 T>G# | 2,3,4,6   | died of respiratory arrest              | (24)      |
| 2  | 26 days   | F      | newborn   | Uncontrollable acidosis; hypoglycemia; cardiac failure                        | neonatal  | HADHA      | homo c.1689+2 T>G# | 2,3,4,6   | died of multi-organ failure              | (24)      |
| 3  | 21/2 weeks| F      | 1 weeks   | Hypoglycemia; metabolic crisis; hepatopathy; hypotonia; cardiomyopathy; seizures| neonatal  | HADHA      | homo c.1528G>C   | 4,6       | died of cardiorespiratory failure        | (30)      |
| 4  | 9 months  | F      | neonatal  | Urinary protein +; dicarboxyl aciduria; failure to thrive; hypoglycemia hepatopathy; hypotonia; cardiomyopathy; retinopathy; neuropathy| neonatal  | HADHA      | homo c.1528G>C   | 2,4       | died of respiratory failure              | (30)      |
| 5  | 14 years  | F      | <5 months | Hepatomegaly; hypoglycemia; episodes of RM; cardiomyopathy; retinopathy; seizures; generalized seizures; acute hepatic failure; cardiac failure| infant    | HADHA      | hetero c.1528G>C  | <0.8      | episodes of RM resolved; acute hepatic and cardiac failure stabilized; significant learning difficulties at age 7; PN and PR identified at age 14 | (23)      |
| 6  | 14 years  | F      | 1 year 5 months | Hypoglycemia; hepatopathy; hypotonia; cardiomyopathy; retinopathy; seizures neuropathy; retardation | infant    | HADHA      | homo c.1528G>C   | 4,6       | hypoglycemia and acute deteriorations subsided; heart and liver no longer enlarged; CK intermittently elevated without symptoms of RM; occasional tonic-clonic seizures; | (30)      |
| 7  | 9 months  | F      | 4 months  | Hypoglycemia; metabolic crisis hepatopathy; hypotonia; cardiomyopathy; retinopathy; seizures; retardation | infant    | HADHA      | homo c.1528G>C   | 2,4       | died of pneumonia, cardiorespiratory failure | (30)      |
| 8  | 10 months | M      | 6–10 months | Motor retardation; metabolic crisis hypoglycemia; hepatopathy hypotonia; cardiomyopathy retinopathy; seizures; retardation | infant    | HADHA      | homo c.1528G>C   | 2,4       | died of cardiorespiratory failure        | (30)      |
| 9  | 10 years  | M      | 4 months  | Hypoglycemia lethargy episodic severe weakness                                | infant    | HADHA      | c.1528G>C, c.1678C>T | 1,2,4,6,7,8 | episodes of RM occurred less frequently; pigmentary retinopathy did not progress after the implementation of DHA; no visual impairment at age 10 | (16)      |
| 10 | 15 years  | F      | 5 months  | Hypotonia; hepatomegaly; hypoketotic hypoglycemia; hypertrophic cardiomyopathy; pigmentary retinopathy; low DHA levels | infant    | HADHA      | homo c.1528G>C   | 1,2,4,8   |Cardiomyopathy fully resolved at 5y; progressive pigmentary retinopathy; stabilization of visual function after DHA supplementation | (20)      |
| No | Age   | Gender | Onset age | Symptom summary                                                                 | Subtype | Gene   | Mutation                          | Treatment | Outcome                                                                                             | Reference |
|----|-------|--------|-----------|---------------------------------------------------------------------------------|---------|--------|-----------------------------------|-----------|-----------------------------------------------------------------------------------------------------|-----------|
| 11 | 19 years | M      | 20 months | progressive weakness, episodic severe weakness                                   | NM      | HADHA  | homo c.845T>A                     | 1,2,3,4,6,7,8 | episodes of RM occurred less frequently; reversal of peripheral sensorimotor neuropathy clinically and by NCS | (16)      |
| 12 | 53 years | M      | 48 years  | recurrent RM                                                                     | NM      | HADHA  | c.1528G>C, c.1A180+3>G           | 1,2,3,5    | no additional episodes of RM                                                                        | (17)      |
| 13 | 13 years | M      | 15 months | gait abnormalities; Achilles tendon tightness; PN; progression of weakness (needed wheelchair at age 10); episodes of RM; extreme fatigability; pigmentary retinopathy | NM      | HADHB  | c.341A>G                          | 1,4,7,9,8 (age 12) | marked improvement in mobility and general strength; NCS showed improvement                          | (20)      |
| 16 | 20 years | F      | 40 days   | shuddering attacks with reduced consciousness; hypocalcemia hypoparathyroidism; child-onset axonal motor sensory polyneuropathy; muscle pain and cramps after exercise; RM preceded by fever, vomiting, and diarrhea | NM      | HADHB  | c.209+1G>C, c.980T>C             | 2,3,4,9,10 | exercise endurance improved                                                                   | (19)      |
| 17 | 14 years | M      | 1–2 years | severely disabling neuropathy; episode of RM started at 13.5 years of age        | NM      | HADHB  | c.607C>T, c.881C>T              | 1,2,3,7,8 | weakness significantly improved                                                                | (16)      |
| 18 | 29 years | F      | 6 years   | child-onset progressive PN; episodic RM started at age 24                        | NM      | HADHB  | c.490G>A, c.686G>A              | 1,2,3,4,5,6,7 | no more episode of RM; weakness and exercise endurance improved                               | present   |

*monozygotic twins; # the mutation lead to the skipping of exon 16 with an in-frame 69-bp deletion; ⋄ short-term dietary treatment (not described in detail). NM, neuromuscular subtype; NCS, nerve conduction studies; PN, peripheral neuropathy; RM, rhabdomyolysis. Treatment points: 1: avoidance of prolonged fasting; 2: restriction of long-chain fatty acids; 3: supplementation of medium-chain triglyceride oil; 4: low-fat high-carbohydrate diet; 5: daily multivitamin; 6: L-carnitine supplementation; 7: avoidance of prolonged exercise; 8: docosahexanoic acid (DHA) supplementation; 9: cornstarch supplementation at night; 10: maltodextrin.
REFERENCES

1. El-Fakhri M, Middleton B. The existence of an inner-membrane-bound, long acyl-chain-specific 3-hydroxyacyl-CoA dehydrogenase in mammalian mitochondria. Biochim Biophys Acta. (1982) 713:270–9. doi: 10.1016/0005-2760(82)90224-2

2. Uchida Y, Izai K, Orii T, Hashimoto T. Novel fatty acid beta-oxidation enzymes in rat liver mitochondria. I. Purification I, and properties of enoyl-coenzyme A (CoA) hydratase/3-hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase trifunctional protein. J Biol Chem. (1992) 267:1034–41. doi: 10.1016/S0021-9258(18)43891-3

3. Carpenter K, Middleton B, Pollitt R. Purification of long-chain 3-hydroxyacyl-CoA dehydrogenase from human infant liver. Prog Clin Biol Res. (1992) 375:75–84.

4. Kamiyo T, Aoyama T, Komiyama A, Hashimoto T. Structural analysis of trifunctional protein. Biochem Biophys Res Commun. (1994) 199:818–25. doi: 10.1016/bbrc.1994.1302

5. Spierkerkoetter U, Lindner M, Santner R, Grotzeke M, Baumgartner M R, Boehles H, et al. Management and outcome in 75 individuals with long-chain fatty acid oxidation defects: results from a workshop. J Inherit Metab Dis. (2009) 32:488–97. doi: 10.1055/s-0054-260159-9

6. Bo R, Yamada K, Kobayashi H, Janiyan P, Hasegawa Y, Taketani T, et al. Clinical and molecular investigation of 14 Japanese patients with complete TFP deficiency: a comparison with Caucasian cases. J Hum Genet. (2017) 62:809–14. doi: 10.1038/jhg.2017.52

7. Magy L, Mathis S, Masson GL, Goizet C, Tazar M, Vallat JM. Updating the classification of inherited nephropathies: Results of an international survey. Neurology. (2018) 90:e870–6. doi: 10.1212/WNL.0000000000005074

8. Timmerman V, Strickland AV, Zuchner S. Genetics of Charcot-Marie-Tooth (CMT) Disease within the Frame of the Human Genome Project Success. Genes (Basel). (2014) 5:13–32. doi: 10.3390/genes5010013

9. Gutmann L, Shy M. Update on Charcot-Marie-Tooth disease. Curr Opin Neurol. (2015) 28:462–7. doi: 10.1097/WCO.0000000000000237

10. Bird TD. Charcot-Marie-Tooth (CMT) hereditary neuropathy overview. In: GeneReviews. Available online at: https://www.ncbi.nlm.nih.gov/books/NBK1358/.

11. Hong YB, Lee JH, Park JM, Choi YR, Hyun YS, Yoon BR, et al. A compound heterozygous mutation in HADHB gene causes an axonal Charcot-Marie-Tooth disease. BMC Med Genet. (2013) 14:125. doi: 10.1186/1471-2350-14-125

12. Lu Y, Wu R, Meng L, Li H, Liu J, Zao Y, et al. HADHB mutations cause infantile-onset axonal Charcot-Marie-Tooth disease: A report of two cases. Clin Neuropathol. (2018) 37:232–8. doi: 10.5414/NP10197

13. Khani M, Tahiery H, Shamsiri H, Moazzene H, Hardy J, Bras JT, et al. Deep geno- and phenotyping in two consanguineous families with CMT2 reveals HADHA as an unusual disease-causing gene and an intronic variant in GDAP1 as an unusual mutation. J Neurol (2021) 268:640–50. doi: 10.1007/s00415-020-10171-4

14. Scacco RS, Gardner AR, Piteathly RD, Zanotelli E, Becker J, Holton JL, et al. Rhabdomyolysis: a genetic perspective. Orphanet J Rare Dis. (2015) 10:51. doi: 10.1186/s13023-015-0264-3

15. Diebold I, Schön U, Horvath R, Schwarz O, Holinski-Feder E, Kölbl H, et al. HADHA and HADHB gene associated phenotypes - Identification of rare variants in a patient cohort by Next Generation Sequencing. Mol Cell Probes. (2019) 44:14–20. doi: 10.1016/j.mcp.2019.01.003

16. Spierkerkoetter U, Bennett MJ, Ben-Zeev B, Strauss AW, Tein I. Peripheral neuropathy, episodic myoglobinuria, and respiratory failure in deficiency of the mitochondrial trifunctional protein. Muscle Nerve. (2004) 29:66–72. doi: 10.1002/mus.10500

17. Liewluck T, Mundi MS, Mauermann ML. Mitochondrial trifunctional protein deficiency: a rare cause of adult-onset rhabdomyolysis. Muscle Nerve. (2013) 48:989–91. doi: 10.1002/mus.23959

18. Yamamoto Y, Matsuji, Hiramatsu Y, Miyazaki Y, Nodera H, Izumi Y, et al. Mitochondrial trifunctional protein deficiency: an adult patient with...
19. van Vliet P, Berden AE, van Schie MKM, Bakker JA, Heringhaus C, Guan et al. HADHB Mutations With Charcot-Marie-Tooth Manifestations

20. Hayes B, Lynch B, O'Keefe M, Monavari AA, Treacy EP. Long chain fatty acid oxidation defects in children: importance of detection and treatment options. *Ir J Med Sci.* (2007) 176:189–92. doi: 10.1007/s11845-007-0025-y

21. Liu ZR, Dong HL, Ma Y, Wu ZY. Identification and functional characterization of mutations within HADHB associated with mitochondrial trifunctional protein deficiency. *Mitochondrion.* (2019) 49:200–05. doi: 10.1016/j.mito.2019.09.004

22. Fu X, Zheng F, Zhang Y, Bao X, Wang S, Yang Y, et al. Mitochondrial trifunctional protein deficiency due to HADHB gene mutation in a Chinese family. *Mol Genet Metab Rep.* (2015) 5:80–4. doi: 10.1016/j.mgmr.2015.10.015

23. Naiki M, Ochi N, Kato YS, Purevsuren J, Yamada K, Kimura R, et al. Mutations in HADHB, which encodes the beta-subunit of mitochondrial trifunctional protein, cause infantile onset hypoparathyroidism and peripheral polyneuropathy. *Am J Med Genet A.* (2014) 164A:1180–7. doi: 10.1002/ajmg.a.36434

24. Choi JH, Yoon HR, Kim GH, Park SJ, Shin YL, Yoo HW. Identification of novel mutations of the HADHA and HADHB genes in patients with mitochondrial trifunctional protein deficiency. *Int J Mol Med.* (2007) 19:81–7. doi: 10.3892/immm.19.1.81

25. Yagi M, Lee T, Awano H, Tsuchi M, Tajima G, Kobayashi H, et al. A patient with mitochondrial trifunctional protein deficiency due to the mutations in the HADHB gene showed recurrent myalgia since early childhood and was diagnosed in adolescence. *Mol Genet Metab.* (2011) 104:556–9. doi: 10.1016/j.ymgme.2011.09.025

26. Purevsuren J, Fukao T, Hasegawa Y, Kobayashi H, Li H, Mushimoto Y, et al. Clinical and molecular aspects of Japanese patients with mitochondrial trifunctional protein deficiency. *Mol Genet Metab.* (2009) 98:372–7. doi: 10.1016/j.molgenet.2009.07.011

27. Song P, Guan Y, Chen X, Wu C, Qiao A, Jiang H, et al. Frameshift mutation of Timm8a1 gene in mouse leads to an abnormal mitochondrial structure in the brain, correlating with hearing and memory impairment. *J Med Genet.* (2020) 58:619–27. doi: 10.1136/jmedgenet-2020-106925

28. Boutron A, Acquaviva C, Vianey-Sabathan, D, Lonlay P, de Baulny HO, Guflon N, et al. Comprehensive cDNA study and quantitative analysis of mutant HADHA and HADHB transcripts in a French cohort of 52 patients with mitochondrial trifunctional protein deficiency. *Mol Genet Metab.* (2011) 103:341–8. doi: 10.1016/j.molgenet.2011.04.006

29. Dagher R, Massie R, Gentili BJ. MTP deficiency caused by HADHB mutations: Pathophysiology and clinical manifestations. *Mol Genet Metab.* (2021) 133:1–7. doi: 10.1016/j.molgenet.2021.03.010

30. Tyini T, Palottie A, Vinnikka L, Valanne L, Salo MK, von Dobeln U, et al. Long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency with the G1528C mutation: clinical presentation of thirteen patients. *J Pediatr.* (1997) 130:67–76. doi: 10.1016/S0022-3476(97)00312-3

31. Gillingham MB, Purnell JQ, Jordan J, Stadler D, Haqq AM, Harding CO. Effects of higher dietary protein intake on energy balance and metabolic control in children with long-chain 3-hydroxy acyl-CoA dehydrogenase (LCHAD) or trifunctional protein (TFP) deficiency. *Mol Genet Metab.* (2007) 90:64–9. doi: 10.1016/j.ymgme.2006.08.002

32. Spiekeroetter U, Lindne M, Santer R, Grotzke M, Baumgartner MR, Boehles H, et al. Treatment recommendations in long-chain fatty acid oxidation defects: consensus from a workshop. *J Inherit Metab Dis.* (2009) 32:498–505. doi: 10.1007/s10545-009-1126-8

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

*Copyright © 2021 Guan, Zhang, Shen, Zhou, Shang, Peng, Hu and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.*

---

**Publisher's Note:**

*All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

*Copyright © 2021 Guan, Zhang, Shen, Zhou, Shang, Peng, Hu and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.*

---